Bold claim: The FDA is moving away from its long-standing requirement of two rigorous studies for drug approvals, signaling a major shift toward speed and flexibility. But here’s where it gets controversial: does fewer trials compromise safety and long-term efficacy? And this is the part most people miss: the change comes with a stated aim to accelerate access to new medicines while still relying on alternative evidence beyond a second trial.
Overview of the change
- The FDA plans to adopt a default position that one well-supported study, along with additional evidence, could be sufficient for approving new drugs and other novel health products. This shift is advocated by FDA Commissioner Dr. Marty Makary and senior deputy Dr. Vinay Prasad, who published the commentary in the New England Journal of Medicine.
- The move is framed as a response to advances in drug research that make studies more precise and scientifically robust, suggesting that requiring two trials may no longer be necessary in many cases.
Context and implications
- Since taking the helm last year, Makary has issued directives aimed at shortening review timelines. These include encouraging the use of artificial intelligence in FDA workflows and piloting shorter one-month assessments for certain drugs deemed to serve national interests.
- The policy is positioned as a general shift, but it contrasts with the FDA’s more cautious stance on other products, such as vaccines, where approvals may still hinge on more extensive testing.
- Historically, the two-trial standard dates back to early 1960s law, which required data from adequate and well-controlled investigations. The intent was to ensure results weren’t flukes and could be reproduced, especially for serious or life-threatening conditions.
What’s changing and why some see it as sensible
- In recent decades, regulators have increasingly accepted single trials for certain indications, particularly for rare or deadly diseases where large patient populations are hard to recruit. In the last five years, around 60% of first-in-class drugs were approved based on a single study.
- The new proposal argues that as biological understanding grows, a single solid trial supplemented by supporting data may adequately establish a drug’s value and safety for many common diseases that previously faced stricter testing.
What supporters and skeptics are saying
- Supporters like Makary, Prasad, and former FDA drug director Janet Woodcock contend that the shift reflects current scientific capabilities and can speed access to beneficial therapies without sacrificing patient protection.
- Skeptics warn that the reduction in duplication could heighten risks if initial studies overstate benefits or miss rare adverse effects. They note that implementation will be critical and that industry reaction remains mixed and uncertain.
Regulatory balance and practical considerations
- The FDA’s future approach may hinge on how trials are designed, what supplementary evidence is required, and how post-approval monitoring is enforced to catch safety signals after products reach the market.
- The agency’s stance on vaccines, gene therapies, and other advanced modalities may diverge from the new drug approval pathway, reflecting the complexity and risk profile of these technologies.
Bottom line and forward look
- If the FDA implements this one-study default with robust supporting evidence, it could unleash a wave of new drug development and faster patient access—especially for widespread conditions where there’s strong biology and meaningful endpoints.
- Yet the roadmap for how to guarantee safety and real-world effectiveness remains a topic of debate, and stakeholders will be watching closely how the policy is operationalized in practice.
What do you think? Should the FDA lean more toward speed with fewer trials, or should two well-conducted trials remain the standard for broad public health protection? Do you trust the emphasis on emerging scientific methods to substitute for replication, or would you prefer a stronger emphasis on confirmatory data before approval? Share your view in the comments.
